Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141274 | 0.96 | — | — | |
| SCHEMBL2712401 | 0.92 | TP53 (0.46) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL9254730 | 0.89 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL1077444 | 0.89 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL28204907 | 0.89 | TP53 (0.50) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL2329063 | 0.84 | — | — | |
| Benzene SCHEMBL27966857 | 0.81 | TP53 (0.44) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL21245516 | 0.78 | TP53 (0.32) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL260160 | 0.77 | — | — | |
| SCHEMBL12133372 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025201533-A1 | NOVEL ACIDIC COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) | 2025-10-02 | — | — | WO | disclosed |
| WO-2025201532-A1 | NOVEL PEGYLATION COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (SHANGHAI) LIMITED., CO. (CN) | 2025-10-02 | — | — | WO | disclosed |
| WO-2024208228-A1 | NOVEL COMPOUNDS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-10-10 | — | — | WO | disclosed |
| CN-108558871-B | Tricyclic compounds as anticancer agents | 百时美施贵宝公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3466949-A1 | TRICYCLIC COMPOUND AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3087071-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-9751879-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2447287-B1 | POLYETHYLENE RESIN, CATALYST USED FOR PRODUCTION OF THE SAME, METHOD FOR PRODUCING THE SAME, HOLLOW PLASTIC MOLDED ARTICLE CONTAINING POLYETHYLENE RESIN, AND USE OF THE HOLLOW PLASTIC MOLDED ARTICLE | JAPAN POLYETHYLENE CORP (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3087071-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9458156-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| US-9193809-B2 | Polyethylene based resin, producing catalyst for the same, method for producing the same, hollow plastic molded article containing polyethylene based resin, and use of the same | JAPAN POLYETHYLENE CORPORATION (JP) | 2015-11-24 | — | — | US | disclosed |
| WO-2015100282-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | WO | disclosed |
| EP-2447287-A1 | POLYETHYLENE RESIN, CATALYST USED FOR PRODUCTION OF THE SAME, METHOD FOR PRODUCING THE SAME, HOLLOW PLASTIC MOLDED ARTICLE CONTAINING POLYETHYLENE RESIN, AND USE OF THE HOLLOW PLASTIC MOLDED ARTICLE | Japan Polyethylene Corporation (JP) | 2012-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | TP53 1/4885KDM4E 1945/4885GMNN 409/4885 |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | TP53 1/4885KDM4E 2234/4885GMNN 811/4885 |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | TP53 1/4885KDM4E 2234/4885GMNN 811/4885 |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | TP53, TK2, TOP2A | TP53 1/4885KDM4E 2036/4885GMNN 459/4885 |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | TP53 1/4885KDM4E 2234/4885GMNN 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.